December 27, 2023 7:59am
Unseen since the Greek hero Odysseus won a competition by shooting an arrow through the tiny hole in a dozen ax heads or Harvard Apparatus GN (HRGN) will ever be a U.S. investable company!
Subscription is coming, it is not conscription but, an offer to join our collective of like-minded investors! Join me … in the NO spin zone.
Question: WHY does Chinese investor DST Capital and Beijing based D. Phone and its sub Dixintong Technology Group need - Harvard Apparatus GN (OTCQB: HRGN) an OTC listed money losing ($90.1 M since split from HBIO) company that resides in the middle of medical and scientific innovation in America? A Ponzi Scheme or just a MSS (Chinese Security Servies) “plant” – check the Beijing, China officers, directors and employees and from where the “investment/money” flows aligned with Lui Dong Hai, chairman of D. Phone, the largest smartphone retailer in China; also, the husband of Mrs. bin Zhao, who resides in Weston, Ma. of DST Capital?
Never leave an investor uninformed!
Remember that overnight action in a.m. futures and global markets doesn't necessarily translate into actual trading in the today’s market session.
The pre-open Dow futures are DOWN -0.07% or -27 points), the S&P is DOWN -0.05% or (-2 points) as the Nasdaq is DOWN -0.03% or (-5 points)
Stock futures were down and still fluctuating- on Wednesday
European markets were higher,
Asia Pacific markets were higher
Henry’omics:
We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies …
The stock market rally enjoyed modest gains Tuesday with the Dow closing UP +159.36 points or +0.43%, the S&P closed UP +20.12 points or +0.42% while the Nasdaq closed UP +81.60 points or +0.54%
Tuesday, RegMed Investors (RMi) Closing Bell: “holiday cheer is still with us as cell and gene therapy sector continues to cascade” … https://www.regmedinvestors.com/articles/13258
Q4: December – 1 holiday, 10 positive and 7 negative closes
- November – 11 positives, 1 holiday and 10 negative closes
- October – 1 sick day, 9 positive and 12 negative closes
Companies in my headlights – It’s your decision; I provide ideas and context:
I post about “indication intelligence” devoting my time to collection and analysis of information to assist investors with insight into sector vulnerabilities and strengths. A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.
I am passing on forecasting the daily indications; it’s just mixed signals, followed by a weak aftermarket as markets follow November’s end … take gains as to those who WILL seek to recapitalize cash positions by discounted stock and pricing offerings!
If I was to make a “bet”:
BioLife Solutions (BLFS) closed up +$0.63 with a negative -$0.16 or -0.96% pre-open indication
Blueprint Medicine (BPMC) closed UP $1.98 with a negative -$0.80 or -0.88% pre-open indication
…With Sell-into-Strength option of:
CRISPR Therapeutics (CRSP) closed up +$1.66 with a positive +$0.47 or +0.72% pre-open indication
Intellia Therapeutics (NTLA) closed up +$0.98 with a positive +$0.53 or 1.64% pre-open indication
The BOTTOM LINE: What hasn’t been said to date …
Again, and again – I say what changes … as I reiterate … “I remain a skeptic, as electronic trading remains the impetus to, I believe a cell and gene therapy sector’s artificial high” … as proven today yet again!
“This week is best described as “the quiet before the storm.” I expect that most stocks will meander higher on light trading volume, before gapping higher in the new year when trading volume naturally rises,” wrote Navellier & Associates founder Louis Navellier in a research note.
“I also hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!” If I have learned one thing as a former research analyst in a venture and public fund, operating executive, x-military officer and x-FBI, a former adjunct (MBA) business school professor now a journalist; my life and your portfolio are largely tied to our knowledge of price movements and questioning pricing targets.
It's time to think ahead to January’s beginning to get those tax losses to further filings.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.
